Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Wasle, I; Gamerith, G; Kocher, F; Mondello, P; Jaeger, T; Walder, A; Auberger, J; Melchardt, T; Linkesch, W; Fiegl, M; Mian, M.
Non-pegylated liposomal doxorubicin in lymphoma: patterns of toxicity and outcome in a large observational trial.
Ann Hematol. 2015; 94(4):593-601
Doi: 10.1007/s00277-014-2250-6
Web of Science
PubMed
FullText
FullText_MUG
- Co-Autor*innen der Med Uni Graz
- Linkesch Werner
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- The anthracycline doxorubicin plays a major role in the treatment of lymphoproliferative disorders. However, its use is often limited due to cardiac toxicity, which seems to be much less in the liposomal non-pegylated formulation (Myocet®). The aim of this study was the evaluation of efficacy and toxicity of Myocet®-containing treatment regimens, with a focus on cardiotoxicity during treatment in lymphoma patients. A total of 326 consecutive patients, treated between March 2008 and December 2013 in 11 Austrian and 1 Italian cancer centers, were retrospectively assessed. Patients' baseline and treatment-related parameters were obtained by reviewing hospital records. Median age was 74 years (range 26-93). The most common histology was DLBCL (60 %), followed by FL (13 %) and MCL (8 %). At least one cardiovascular comorbidity was present in 72 % of patients. Most common grade 3/4 toxicities were hematologic, namely, leukopenia, neutropenia, thrombocytopenia, and febrile neutropenia in 44, 40, 17, and 16 %. Overall, 43 patients suffered a cardiac event (any grade) with most patients developing congestive heart failure. Parameters significantly associated with severe cardiac events (grades 3-5) were the presence of cardiovascular comorbidities, chronic obstructive pulmonary disease, and elevated baseline NT-proBNP. Treatment response after first line Myocet®-containing therapy was ≥58 % among all entities (range 58-86 %) and therefore comparable to those of conventional therapeutic regimens. Herein, we provide a detailed toxicity profile of Myocet®-containing chemotherapy regimens. Despite the high rate of patients with preexisting comorbidities, the number of adverse events was encouraging. However, these results need to be confirmed in a prospective randomized trial.
- Find related publications in this database (using NLM MeSH Indexing)
- Adult -
- Aged -
- Aged, 80 and over -
- Antibiotics, Antineoplastic - therapeutic use
- Doxorubicin - analogs & derivatives
- Doxorubicin - therapeutic use
- Drug-Related Side Effects and Adverse Reactions - epidemiology
- Female -
- Humans -
- Lymphoma - drug therapy
- Lymphoma - epidemiology
- Male -
- Middle Aged -
- Polyethylene Glycols - therapeutic use
- Retrospective Studies -
- Treatment Outcome -
- Find related publications in this database (Keywords)
- Anthracycline
- Cardiac toxicity
- Lymphoma
- Myocet
- R-CHOP